Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Hayoung Meditech Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, REDWOOD, CHRISTOPHER EVAN, and is in 1 distinct art unit.
REDWOOD, CHRISTOPHER EVAN is the busiest examiner for the company, with 1 pending office action. This single action represents the total active prosecution for Hayoung Meditech Inc. in the Biotechnology & Pharmaceuticals field. The 1 distinct art unit indicates a specific technical focus for the company's current filing.
The prosecution is concentrated under 1 distinct examiner. Practitioners can focus on the specific examination style of REDWOOD, CHRISTOPHER EVAN. With only 1 pending office action, the company's immediate patent success in the Biotechnology & Pharmaceuticals sector depends on this single matter in 1 distinct art unit. Careful preparation for the 1 pending office action is necessary to advance the company's intellectual property goals.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REDWOOD, CHRISTOPHER EVAN | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18363123 | ANTI-INFLAMMATORY COMPOSITION COMPRISING N-BENZYL-N-METHYLDECAN-1-AMINE OR A DERIVATIVE THEREOF AS AN ACTIVE INGREDIENT | REDWOOD, CHRISTOPHER EVAN | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18363123 | ANTI-INFLAMMATORY COMPOSITION COMPRISING N-BENZYL-N-METHYLDECAN-1-AMINE OR A DERIVATIVE THEREOF AS AN ACTIVE INGREDIENT | REDWOOD, CHRISTOPHER EVAN | 1629 | §103 | Final Rejection | — | Pending | Aug 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHayoung Meditech Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Christopher Evan Redwood has the most, with 1 of Hayoung Meditech Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
